Studies from Sungkyunkwan University Add New Findings in the Area of Adverse Drug Reactions (Gender Differences In the Adverse Events Associated With Cardiovascular Drugs In a Spontaneous Reporting System In South Korea): Drugs and Therapies – Adverse Drug Reactions

2022 SEP 28 (NewsRx) -- By a News Reporter-Staff News Editor at Insurance Daily News -- Investigators discuss new findings in Drugs and Therapies - Adverse Drug Reactions. According to news reporting out of Suwon, South Korea, by NewsRx editors, research stated, “Studies on disease-related gender differences in pharmacodynamics and pharmacokinetics are prevalent; however, gender differences in the drug-related adverse events have not been systemically described. To explore gender differences in the adverse events associated with cardiovascular drugs using a spontaneous reporting system.”

Financial support for this research came from Korea Institute of Drug Safety and Risk Management.

Our news journalists obtained a quote from the research from Sungkyunkwan University, “This study was conducted using the Korea adverse event reporting system and national health insurance databases. The number of reported adverse events was divided by the number of patients diagnosed with cardiovascular diseases (Korean Standard Classification of Disease, 7th Revision, I05-I70) and prescribed cardiovascular drugs. We calculated adverse event reporting rates per 100,000 persons and the reporting ratio for women, compared with men. Reporting ratios across the groups of adverse events and cardiovascular drugs. We identified 27,533 adverse events associated with cardiovascular drugs and 9,413,666 patients with cardiovascular disease. Compared with men, reporting ratios of women were higher in the following categories: Overall (1.09, 95% CI, 1.06-1.11), beta blockers (1.20, 95% CI, 1.05-1.39), and calcium channel blockers (1.14, 95% CI, 1.03-1.27). For the adverse events, the reporting ratio was 1.34 (95% CI, 1.14-1.58) for musculoskeletal disorders and 2.54 (95% CI, 2.10-3.07) for oedema in women. Our findings on differential adverse events reporting rates associated with the cardiovascular drugs between women and men provide an evidence on possible gender differences in wide range of pharmacotherapy.”

According to the news editors, the research concluded: “A clear understanding of the relationship between drug-induced adverse events and gender will aid in the development of therapeutic interventions being tailored to the individual patients.”

This research has been peer-reviewed.

For more information on this research see: Gender Differences In the Adverse Events Associated With Cardiovascular Drugs In a Spontaneous Reporting System In South Korea. International Journal of Clinical Pharmacy, 2021;43(4):1036-1044. International Journal of Clinical Pharmacy can be contacted at: Springer, Van Godewijckstraat 30, 3311 Gz Dordrecht, Netherlands. (Springer - www.springer.com; International Journal of Clinical Pharmacy - http://www.springerlink.com/content/2210-7703/)

Our news journalists report that additional information may be obtained by contacting Ju-Young Shin, Sungkyunkwan University, School of Pharmacy, 2066 Seobu Ro, Suwon, South Korea. Additional authors for this research include Han-Heui Park, Ju Hwan Kim, Dongwon Yoon and Hyesung Lee.

The direct object identifier (DOI) for that additional information is: https://doi.org/10.1007/s11096-020-01212-z. This DOI is a link to an online electronic document that is either free or for purchase, and can be your direct source for a journal article and its citation.

(Our reports deliver fact-based news of research and discoveries from around the world.)